Sezary syndrome (SS) and mycosis fungoides are the most common forms of primary cutaneous T-cell lymphomas. SS is the leukemic variant of cutaneous T-cell lymphoma, characterized by CD4 þ T cells, the Sezary cells, circulating in the peripheral blood, clonally expanded and identified by the rearrangement of T-cell receptor. The disease has an aggressive course with an average survival of 2-4 years. 1 Allogeneic hematopoietic SCT (HSCT) provides a potentially curative approach for such patients, suggesting a role for graft-versus-tumor effect exerted by donor T cells. 2 Because of toxicity and high risk of non-relapse mortality, patients heavily pretreated or of advanced age and/or with comorbidities are generally considered ineligible for a myeloablative allogeneic transplant. However, the use of conditioning regimens at reduced intensity (RIC) made allogeneic transplant feasible in these unfit patients. 2 In 2001, a 56-year-old woman with a diagnosis of SS sequentially received several lines of therapy in the form of extracorporeal photopheresis, a-IFN and steroids, obtaining only partial responses of short duration.
In March 2005 and shortly after initial response to alemtuzumab, disease progression occurred and the patient was in stage IVA 1 according to the ISCL/EORTC revised classification. 3 She underwent an unmanipulated allogeneic BM SCT from her HLA-identical sister after an RIC regimen consisting of fludarabine (80 mg/m Early in the post transplant period, no particular toxicity occurred. Skin lesions improved slightly and at the flow cytometry analysis the V-beta TCR repertoire in CD4 þ T cells decreased from 95 to 5%. Skin lesions persisted at day 120 post transplant; a skin biopsy revealed a TCR clonal infiltrate and immunosuppressive therapy was discontinued. One month later (day 150), the patient developed acute GVHD (skin grade I), confirmed by skin biopsy, which improved spontaneously without any treatment.
At 9 months from transplant, the patient developed a generalized erythroid rash with severe pruritus, clinically diagnosed as acute GVHD (skin grade II), that responded quickly to prednisone at 2 mg/kg/day. Two months later, during steroid tapering, progression of skin lesions and axillary lymphadenopathy was observed. Skin biopsy confirmed an SS relapse and the lymph node showed a dermatopathic lymphadenopathy. The clonal CD4 þ T cells increased up to 70% in the peripheral blood, but at the total body CT scan no other lymphadenopathy or organomegaly was documented. The chimerism study confirmed hematopoiesis as being of full donor origin in the bone marrow.
Fourteen months after transplant, the patient received the first donor lymphocyte infusion (DLI) consisting of 1 Â 10 7 /kg CD3 þ cells. After 4 weeks, there were no signs of GVHD and a second DLI was given at a dose of 5 Â 10 7 /kg CD3 þ cells. Two months later, the patient developed acute GVHD (grade II involving skin and upper gastrointestinal tract) confirmed by a biopsy from the gastric mucosa. Steroid therapy (prednisone 1.5 mg/kg/day) was started and a partial response was achieved.
Six months after steroid therapy withdrawal, there was no evidence of TCR rearrangement of CD4 þ T cells either in the skin biopsy or in the peripheral blood. The flow cytometry analysis for circulating clonal lymphocytes at different evaluation points from transplant is shown in Figure 1 .
To date, with a follow-up of 3 years from transplant and 24 months from the first DLI, the patient is alive, in clinical and molecular remission with a limited chronic GVHD of the skin, without any further treatment.
Despite the availability of new drugs, treatment of mycosis fungoides and SS in advanced stage remains a challenge. Discouraging results are reported by the use of autologous HSCT, 4 whereas allogeneic HSCT can induce a durable clinical and molecular remission in advanced SS: 2 more than two-thirds of patients undergoing an allogeneic HSCT remain alive with no evidence of disease. Moreover, a favorable response has been reported using immunomodulatory therapies or following immunosuppression withdrawal after allogeneic HSCT. 5, 6 The success of the RIC regimen in allogeneic HSCT relies on the immunomediated antitumor effect expressed by donor cells while providing a more tolerable conditioning regimen for patients considered at high risk for TRM. Moreover, the results reported for the RIC regimen in allogeneic HSCT in cutaneous T-cell lymphoma patients seem to be encouraging. 7 Our patient received an RIC regimen for allogeneic transplant with very good tolerability. A full donor hematopoietic chimerism was maintained in the marrow even after disease relapse. Disease remission was successfully achieved after DLI. A clear correlation between DLI, achievement and maintenance of disease remission and GVHD/graft-versus-tumor development was observed. This observation confirms that T Sezary cells can be targeted by donor-derived immune cells.
In conclusion, our case further supports that the potential curative effect of the GVHD/graft-versus-tumor observed after an allogeneic transplant in cutaneous T-cell lymphomas is also achievable in patients with SS in an advanced stage. þ detected by cytofluorimetric analysis of the V beta TCR repertoire and correlation with the disease status.
